Skip to content
  • Home
  • About Us
  • Cardiovascular
  • News
  • Home
  • About Us
  • Cardiovascular
  • News
Contact Us
  • Home
  • About Us
  • Cardiovascular
  • News
  • Contact
  • Home
  • About Us
  • Cardiovascular
  • News
  • Contact

Releted Post

AirSeal is selected as a recipient of the first WashU Venture Network Follow-on Investments

Read More »
April 12, 2025

Our co-founder, Dr. Zayed, was recently interviewed by KMOX Radio

Read More »
April 1, 2025

AirSeal is awarded a co-investment of $500,000 from Missouri Technology Corporation (MTC)

Read More »
November 12, 2024

AirSeal is selected as a 2024 Arch Grants recipient, which includes a $75,000 non-dilutive cash award.

Read More »
November 1, 2024

AirSeal is one of the ten teams (selected from hundreds of global applicants) to attend the TMCi Healthtech Accelerator Bootcamp. We are excited to meet other venture teams and TMCi advisors.

https://www.tmc.edu/blog/tmc-innovation-factory-hosts-cohort-17-for-its-healthtech-accelorator-bootcamp/

AirSeal is advancing early, accurate diagnosis of cardiovascular diseases through innovative biomarker technology.

  • Services
  • PAD Diagnostics
  • PAD Guard™ Testing
  • Clinical Trial Support
  • Healthcare Solutions
  • Diagnostic Tech Integration
  • R&D Collaboration
  • Quick Links
  • Home
  • About
  • Cardiovascular
  • News
  • Contact Us
  • Contact Info
  • contact@airsealcv.com
  • 4340 Duncan Ave, St. Louis, MO 63130
  • 021-2323433
  • 021-2323433
© 2023-2025 by AirSeal CardioVascular Inc. Designed & Developed by Steatech